Abstract
Articular cartilage injuries are common in the population. The increment in the elderly people and active life results in an increasing demand for new technologies and good outcomes to satisfy longer and healthier life expectancies. However, because of cartilage’s low regenerative capacity, finding an efficacious treatment is still challenging for orthopedics.

Since the pioneering studies based on autologous cell transplantation, regenerative medicine has opened new approaches for cartilage lesion treatment. Tissue engineering combines cells, biomaterials, and biological factors to regenerate damaged tissues, overcoming conventional therapeutic strategies. Cells synthesize matrix structural components, maintain tissue homeostasis by modulating metabolic, inflammatory, and immunologic pathways. Scaffolds are well acknowledged by clinicians in regenerative applications since they provide the appropriate environment for cells, can be easily implanted, reduce surgical morbidity, allow enhanced cell proliferation, maturation, and an efficient and complete integration with surrounding articular cartilage. Growth factors are molecules that facilitate tissue healing and regeneration by stimulating cell signal pathways.

To date, different cell sources and a wide range of natural and synthetic scaffolds have been used both in pre-clinical and clinical studies with the aim to find the suitable solution for recapitulating cartilage microenvironment and inducing the formation of a new tissue with the biochemical and mechanical properties of the native one. Here, we describe the current concepts for articular cartilage regeneration, highlighting the key actors of this process trying to identify the best perspectives.

Keywords: Cartilage regeneration, Tissue engineering, Scaffolds, Growth factors, Osteochondral defects bioprinting

Introduction
Articular cartilage covers the bony ends of diarthrodial joints; it is a smooth thin hyaline tissue with friction-reducing and load-bearing functions. It lacks blood vessels, lymphatics, and nerves [1]. As for connective tissues, an extracellular matrix (ECM) composed of water, collagens, and proteoglycans surrounds the cells. Chondrocytes are mature secretory scarcely distributed cells located in spaces termed lacunae. They are spread among superficial, middle, deep, and calcified four zones.

Those zones display different cell shapes, secretory patterns, and fiber orientation [2]. The layer of bone below the hyaline cartilage is known as subchondral bone. It has a structural and mechanical function (shock absorber) and can be involved in the etiology or effects of cartilage damages or diseases [3].

Chondral (affecting articular cartilage) and osteochondral (affecting cartilage and the underlying bone) lesions are very common and can appear at any age [4, 5]. In the young population, they are most of traumatic origin (sport or accident), often with ligament and meniscal injuries. Some conditions like osteochondritis dissecans may lead to articular surface disruption and release of...
Tissue engineering

Tissue engineering has represented a new fascinating, and innovative approach to regenerating articular tissue [12]. As reported above, this therapeutic strategy involves the use of cells, scaffolds, and growth factors (GF), trying to mimic the complex three-dimensional microenvironment of the joint that requires the interaction between these different components. Reproducing such complexity is critical, and many issues are still open concerning the ideal cell population, the use of GF and the suitable scaffolds [1, 13].

Cells

Cells can be administered as therapeutic agents to rebuild damaged cartilage in joints. The leading cell types used in treating chondral and osteochondral defects are chondrocytes and mesenchymal stromal cells from various sources [14]. The technique requires that cells are isolated and then expanded ex vivo in a monolayer culture before the implant. In terms of legislation, expanded cells belong to Advanced Therapy Medicinal Products (ATMPs) and must follow specific rules already encoded for conventional drugs and known as Good Manufacturing Practices (GMPs). GMPs entail the standardization and control of medicinal manufacturing, ensuring their safety and reducing contaminations [15].

Autologous chondrocyte implantation

Autologous Chondrocyte Implantation (ACI) is a two-step procedure that has been used in the clinic for many years [16]. In the original ACI technique (first-generation technique), the first step consisted of surgically removing small biopsies of normal cartilage from non-weight-bearing areas of the knee. Chondrocytes were then enzymatically isolated from the biopsies, expanded ex vivo in monolayer culture condition, and, after several weeks, harvested as a cell suspension. In the second step, surgeons injected the cell suspension under a periosteal flap harvested from the proximal medial tibia and previously sutured over the cartilage. Chondrocyte expansion was deemed necessary due to cartilage cell scarcity [17].

ACI that uses suspended cultured chondrocytes with a covering of collagen type I/III membrane is considered a second-generation. Third-generation ACI comprises those procedures that deliver autologous cultured chondrocytes using cell carriers or cell-seeded scaffolds. These second and third generation modifications are also known as autologous chondrocyte implantation using collagen membrane (C-ACI), membrane-associated autologous chondrocyte implantation (MACI), and scaffold-based ACI [13, 18]. These procedures were introduced in the clinical practice one decade ago, showing similar results while at the same time overcoming most of the concerns related to the first-generation ACI. The use of scaffolds to create a cartilage-like tissue in a three-dimensional culture system allows for the optimization of the procedure from both the biological and surgical points of view [19, 20].

Although good clinical radiological and histological outcomes of the different ACI procedures, one of the main drawbacks is the need for a cell expansion phase which is long-lasting, complicated, and expensive primarily due to GMPs requirements. Moreover, the need for two hospitalizations increases the risk for the patients
and the costs for the public health system. For all these reasons, investigations have been moving towards different cell populations as reported below [9, 21, 22].

**Mesenchymal stromal cells (MSC)**

Stromal cells from various sources are currently available for cartilage regeneration. This is due to their ability to proliferate in culture and directionally differentiate by synthesizing structural and functional hyaline ECM molecules. Moreover, they can release many anti-inflammatory, anti-apoptotic, and immuno-modulatory factors favoring the healing process [23]. Many studies have reported benefits in treating cartilage injuries with adult bone marrow-derived MSC [23]. Adipose-derived stem cells (ASC) have also drawn attention for their analogy with bone marrow ones, but with easier harvesting, a higher cell density, and proliferation. Other sources of stem cells investigated for cartilage repair include muscle, synovial membrane, trabecular bone, dermis, blood, umbilical cord blood, and periosteum [23]. Although various successful applications in cartilage regeneration, several problems remain, like stem cell heterogeneity and premature differentiation during in vitro expansion [24]. Induced pluripotent stem cells (iPSCs) have a promising potential for cartilage regeneration. Besides, they allow overcoming limitations associated with current cell sources since large numbers of cells can derive from small starting populations. However, issues related to genomic modifications still need addressing [25].

Genetically modified cells showed the ability to potentiate cartilage regeneration. Transfected genes inducing chondrogenic differentiation, synthesis of a hyaline matrix, and release of pro-inflammatory factors differentiation are feasible. Gene transfection may be systemic or local, ex vivo or in vivo. Because cartilage injuries are not life-threatening, it is critical to ensure a safe procedure [26].

MSC, as a pure cell population, require the selective elimination of cells that do not express their typical markers. Recently, new insight turned into the role of the surrounding MSC microenvironment (or “niche”) that also encloses ECM, accessory cells, adhesion molecules, growth factors, cytokines, and chemokines. Stem cell activity is not only the expression of intrinsic capabilities but also the result of the interactions with the “niche”. It is the whole “niche” that can support the healing process. No cell selection and expansion in the laboratory are necessary, and a single operative procedure is effective [27–29].

In recent years, also articular cartilage regeneration research moved towards the use of the stem cell “niche” in the form of concentrates such as Bone Marrow Concentrate (BMC) and Stromal Vascular Fraction (SVF) from adipose tissue. Both concentrates are obtained with minimal manipulation (no expansion in culture) and provide a less invasive (one-step-surgery) and less expensive (no GMPs) alternative to cultured cells.

Our laboratory investigated the behavior of BMC cells within a hyaluronan-based scaffold. Histological immunohistochemical and molecular results showed the formation of a cartilage-like ECM [30]. We also evaluated BMC chondrogenic and osteogenic potential on a bi-layered scaffold mimicking the osteochondral compartment (collagen and hydroxyapatite). The obtained data demonstrated the ability to reproduce the native osteochondral compartment by generating two separated cartilage and bone zones [31, 32].

SVF obtained from liposapirate contains several cell types like ASCs, ECM fibroblasts, and white and red blood cells. After washing passages, the obtained SVF can be combined with scaffold and soluble factors and administered into the joint. Compared to BMC, SVF ensure easier accessibility and the availability of an increased number of stem cells per gram of tissue [33].

**Cell free products**

In the early stages, it seems that the ability of MSC to differentiate into various cell types played the main therapeutic effect. Later, it emerged that their capacity to release some GF and chemokines play a role (secretome). MSCs secrete bioactive molecules inhibiting apoptosis and the formation of fibrosis or scarring at the injury site; stimulate angiogenesis and blood supply, and mitosis of tissue-specific progenitors. They also secrete immunomodulatory agents that deactivate the T cells surveillance and chronic inflammatory processes. Therefore, the secretome use for tissue regeneration increased, based on its composition of trophic factors (chemokines, cytokines, hormones, and lipid mediators) with paracrine effects on the cells of the local microenvironment [34].

The soluble factors of the secretome can initiate regenerative signaling events also without the use of cells. The therapeutic effect of this biological product in musculoskeletal diseases is a frontier of regenerative medicine. The secretome could overcome the negative aspects of cell use and help concentrate paracrine factors at physiological levels at the injury site.

Although many studies provide strong evidence for the potency of MSC-secreted factors in mediating tissue repair and regeneration, the precise mechanisms of action are still not fully understood [35].

The paracrine action of MSC is not limited to the production of soluble factors but also of many extracellular vesicles (EVs). EVs [36] are involved in intercellular communication by releasing mRNAs and proteins. Besides, they have anti-apoptotic, antifibrotic, pro-angiogenic,
and anti-inflammatory effects. EVs released from tissue-
damaged cells can re-program stem cells’ phenotype by
releasing specific mRNAs or microRNAs. EVs produced by
circulation-recruited or resident MSCs can re-pro-
gram tissue-damaged cells by inducing de-differentiation,
production of soluble paracrine mediators, and initia-
tion of the cell cycle of these cells, thus promoting tissue
regeneration [37].

**Growth factors**

Biologic agents represent an emerging treatment for
several musculo-skeletal pathologies. These agents are
mainly represented by natural GF and anti-inflammatory
mediators that can accelerate tissue healing and regen-
eration. They can act through various mechanisms,
including matrix synthesis and remodeling, cell recruit-
ment and modulation of inflammatory markers and metalloproteinases.

Moreover, GF may influence protein synthesis and cel-
lar interactions, controlling stem cell differentiation.
Bone Morphogenic Protein-2 (BMP-2) regulates osteo-
genesis, Vascular Endothelial Growth Factor (VEGF)
angiogenesis, and Transforming Growth Factor-β1
(TGF-β1) chondrogenesis. The possible role played by
GF in pain reduction and tissue regeneration has gener-
ated a growing interest in their possible therapeutic use
in patients with musculo-skeletal injuries.

Recently, discoveries, combined with knowledge of the
importance and role of growth factors for tissue engi-
neering, have been further developed and deepened [38].
GF facilitate and promote the regeneration of new tis-
ues by interaction with specific transmembrane recep-
tors and regulating protein synthesis within cells. Binding
to the specific growth factor receptor specifically stimu-
lates cell signal transduction pathways that trigger cell
migration, survival, adhesion, proliferation, growth, and
differentiation.

Although GF have great potential to stimulate cartilage
repair, only a limited number of treatments have been
approved by government regulatory agencies for clinical
use [39].

Platelet-rich plasma (PRP) represents an economical
source for obtaining many GF in physiological propor-
tions and has already been widely applied in various fields
of medicine for its property of promoting tissue regener-
ation [12, 40]. PRP can be defined as a blood derivative
product in which platelets are present in high concentra-
tion. Platelets have demonstrated regenerative properties
because they are rich in important GF.

In particular, α platelet granules contain and release
numerous GF including PDGF, TGF-β1, VEGF, Epi-
dermal Growth factor (EGF), Fibroblast Growth Factor
(FGF) and Insulin-like Growth Factor (IGF).

In recent years, PRP has achieved great success in clinical
practice, thanks to its safety and simply preparation
 technique, which allows exploiting its biologically active
content.

PRP has been used successfully in several surgical tech-
niques, obtaining good results in association with microfr-
actures or scaffolds for the treatment of cartilage lesions
[41]. The most significant evidence on PRP is instead for
its intra-articular use in the treatment of osteoarthritis,
especially in the knee. Despite this, the most suitable type
of PRP remains debated, with different preparation meth-
ods available that can give products with different com-
position and properties [42].

**Scaffolds**

Scaffolds are support sustaining three-dimensional (3D)
tissue development. They differ in material composi-
tion, structure, and status. An ideal scaffold should be
biomimetic, biocompatible, biodegradable, and non-
immunogenic; induce cell attachment, growth, and dif-
ferentiation. Once implanted, it should integrate into the
lesion site and support the healing process. It should also
be easy to handle by surgeons, and cost-effective Scaf-
dolds for cartilage regeneration may be natural, or syn-
thetic [43].

Natural materials possess high biocompatibility and
bioactivity. However, show poor mechanical stabil-
ity because of their rapid hydrolysis. A list of the most
known natural materials with the principal advantages
and disadvantages is reported in Table 1.

Synthetic polymers like poly(ethylene glycol) (PEG),
polycaprolactone (PCL), polylactic acid (PLA), poly-
urethane, poly(glycolic acid) (PGA), polyethersulfone
(PES), and polysulfone provide cell attachment, and good
mechanical, physical, and chemical properties. Moreover,
the mechanical properties and degradation time can be
controlled by combining them as copolymers or blends.
Disadvantages consist of the lack of biological proper-
ties and the host organism’s side effects in response to
metabolite production, mainly concerning acids that can
be toxic or induce an inflammatory response [43].

Hybrid scaffolds, such as a combination of collagen-
chitosan- PLA, merge the advantages of synthetic and
natural materials, allowing biocompatible membranes
with defined mechanical properties and tunable degrada-
tion necessary for cartilage regeneration [43].

Studies highlighted the in vitro and in vivo interaction
of cells with scaffolds [44]. Our group had the opportu-
nity to evaluate some natural scaffolds based on collagen
or hyaluronan. We highlighted that scaffold presence
allows the re-creation of physiological-like conditions
whereby cells interact with the biomaterial and produce
| Natural origin scaffolds | Advantages | Disadvantages |
|--------------------------|------------|---------------|
| Hyaluronic acid          | Anionic, non-sulfated glycosaminoglycan (GAG) is present in cartilage ECM. Supports cell attachment through surface receptors like CD44 ECM | Poor mechanical properties, rapid degradation |
| Chondroitin sulfate      | Sulfated GAG is present in cartilage ECM with anti-inflammatory activity, and a role in cell signaling. Easy to be functionalized | Poor mechanical properties, rapid degradation |
| Alginate                 | Negatively charged polysaccharide extracted from brown algae and bacterial sources. High functionality, fast cross-linking, low cost, injectable for bioprinting, structural similarity to GAGs | Poor mechanical strength, low cell-matrix interaction, varying levels of purity due to source variability, immunogenicity |
| Agarose                  | A marine polysaccharide obtained from seaweed. It presents excellent biocompatibility, good stiffness and viscoelasticity. High functionality, thermoreversible gelation, low cost, structural similarity to GAGs | Limited mechanical performance, low bioactivity, poor cell attachment |
| Chitosan                 | An amino polysaccharide polymer derived from chitin and the wastes of the seafood industry. Biocompatible and biodegradable. It possesses antibacterial activity | Poor water solubility in physiological conditions, potential allergenic risks, inferior mechanical properties, low cell adhesiveness, and potential allergic reactions due to its origin |
| Gellan gum               | A linear negatively charged polysaccharide produced by the Sphingomonas group bacteria; pH and temperature responsiveness, structural similarity to GAGs | Weak mechanical strength, poor stability, low bioactivity, relatively high gelation temperature, small temperature window |
| Collagen                 | The main protein component in natural cartilage, displays great biocompatibility and biodegradation without causing inflammation | Poor mechanical properties, potential of immunogenicity, high cost, limited sterilizability |
| Gelatin                  | A derivative of collagen by partial hydrolysis with much lower antigenicity. Biologically active for cellular interaction, low immunogenicity in comparison to collagen, ease of processing and functionalization | Poor mechanical properties, rapid degradation, low thermal stability |
| Silk fibroin             | The major protein component of natural silk. High mechanical strength, low immunogenicity, morphologic flexibility, good sterilizability, usable for cartilage bioprinting, easily available, biocompatible, biodegradable | Source variability, low biodegradability |
| Fibrin                   | Fibrin is a blood protein, well known for its role in clot formation, justifying its use in clinical practice as a hemostatic or a sealant agent. Hydrogels can be prepared from fibrinogen by the enzymatic treatment of thrombin; the advantages are excellent biocompatibility and biodegradability | Weak mechanical properties |
| Cellulose                | One of many polymers found in nature, may enter the composition of carboxymethyl cellulose, and in turn, hydrogel by specific processes | Low integration. No degradability |
a new ECM by the secretion of anabolic, anti-inflammatory, and anti-apoptotic factors [45–50].

A challenge in the design and fabrication of scaffolds is the reproduction of the osteochondral compartment. To this end, composite bilayer or gradient scaffolds mimicking the osteochondral tissue have been developed and evaluated in association with cells. The data obtained demonstrated cell ability to zonally interact and reproduce the native osteochondral compartment by generating separated cartilage- and bone-like zones [5].

Another challenge is the cell seeding onto the scaffold. Conventional method involves the manual/static or the automated/dynamic seeding of cells onto previously fabricated scaffolds. The static seeding allows an uneven cell distribution into the width of the biomaterial. The dynamic seeding carried out with bioreactors (for instance perfusion) favor a more homogenous cell distribution [24]. The recent approach of bioprinting foresees that cells and biomaterial are released together in order to produce a construct. Such options allow a better cell encapsulation and spatial distribution [51].

**Future directions**
In the next decades we will assist to important steps forwards the repair of articular cartilage lesions. The use of iPSCs and or stem cell derivatives such as secretome, EVs could contribute to improve tissue regeneration.

Emerging technologies like Additive Manufacturing three-dimensional (3D) printing should allow for a further improvement of the treatment. 3D printing replicates the damaged tissue shape starting from a patient medical image. It creates scaffolds through the progressive addition of material layer by layer until reaching the desired shape. The technology can mimic cartilage organization, ECM composition, and functional and mechanical properties [52–55].

Indeed, the identification of the ideal cell population, cell-free products, clinical grade growth factors and customized scaffolds could contribute to ameliorate the technique, reducing the time for surgery and enhancing patient recovery.

**Conclusion**
Chondral and osteochondral damages remain a tough challenge for clinicians. Tissue engineering-based strategies have proven feasible for cartilage regeneration with good results on patients’ quality of life. More research needs to find the best combinations of cells, bioactive factors, and scaffolds. More clinical trials should confirm the obtained results. There is also the demand to develop minimally invasive and cost-effective strategies which do not require long-lasting hospitalization.

**References**
1. Camarero-Espinosa S, Rothen-Rutishauser B, Foster EJ, Weder C (2016) Articular cartilage: from formation to tissue engineering. Biomater Sci 4(5):734–767
2. Carballo CB, Nakagawa Y, Sekiya I, Rodeo SA (2017) Basic science of articular cartilage. Clin Sports Med 36:413–425
3. Eisenstein NM, Shepherd D, Espino DM (2019) The role of subchondral bone and its histomorphology on the dynamic viscoelasticity of cartilage bone and osteochondral cores. Osteoarthr Cartil 27(3):535–543
4. Ahmed TA, Hincke MT (2010) Strategies for articular cartilage lesion repair and functional restoration. Tissue Eng Part B Rev 16(3):305–329
5. Al C, Lee Y, Tan XH, Tan S, Hui J, Goh JC (2021) Osteochondral tissue engineering: perspectives for clinical application and preclinical development. J Orthop Translat 30:93–102
6. Jones MH, Williams AM (2016) Osteochondritis dissecans of the knee: a practical guide for surgeons. Bone Jt J 98-B(6):723–729
7. Goldring S, Goldring M (2016) Changes in the osteochondral unit during osteoarthritis: structure function and cartilage-bone crosstalk. Nat Rev Rheumatol 12:632–644
8. Varady NH, Grodzinsky AJ (2016) Osteoarthris year in review 2015: mechanics. Osteoarthr Cartil 24(1):27–35
9. Makris EA, Gomoll AH, Malizos KN, Hu JC, Athanasiou KA (2015) Repair and tissue engineering techniques for articular cartilage. Nat Rev Rheumatol 11(1):21–34
10. Musumeci G, Aiello FC, Szychlinska MA, Di Rosa M, Castrogiovanni P, Mobasheri A (2015) Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression. Int J Mol Sci 16(3):6093–6112
11. Tuan RS, Chen AF, Klatt BA (2018) Cartilage regeneration. J Am Acad Orthop Surg 26(5):303–311
12. Atala A, Raper K, Mikos AG (2012) Engineering complex tissues. Sci Transl Med 4:16012
13. Benes AE, Lykkias MG, Papageorgiou CD, Georgoulis AD (2005) Advances in articular cartilage repair. Injury 36S:514–523
14. Huang BJ, Hu JC, Athanasiou KA (2016) Cell-based tissue engineering strategies used in the clinical repair of articular cartilage. Biomaterials 98:1–22
15. Philippe V, Laurent A, Hirt-Burri N, Abdel-Sayed P, Scaletta C, Schneebeli V, Michetti M, Brunet JF, Applegate LA (2022) Marti, R Retrospective Analysis of Autologous Chondrocyte-Based Cytotherapy Production for Clinical Use: GMP Process-Based Manufacturing Optimization in a Swiss University Hospital. Cells 11:1016
16. Peterson L, Vaissiladis HS, Britberg M, Lindahl A (2010) Autologous chondrocyte implantation: a long-term follow-up. Am J Sports Med 38(6):1117–1124
17. Britberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L (1994) Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 331(14):889–895
18. Devan AK, Gibson MA, Elisseef JH, Trice ME (2014) Evolution of autologous chondrocyte repair and comparison to other cartilage repair techniques. Biomed Res Int 2014:272481

19. Grigolo B, Roseti L, De Franceschi L, Piacentini A, Cattini L, Manfredini M, Facchin A, Grigolo B (2006) Molecular and immunohistological characterization of human cartilage two years following autologous cell transplantation. ABJS Am 87(1):46–57

20. Kon E, Filardo G, Di Martino A, Maracci M (2012) ACI and MACI. J Knee Surg 25(1):17–22

21. Labusca L, Greisser U, Mashayekhi K (2016) Emerging Concepts for Articular Cartilage Regeneration. J Bone Stem Res 2014

22. Phull AR, Eo S, Abbas Q, Ahmed M, Kim S (2016) Applications of chondrocyte-based cartilage engineering: an overview. BioMed Res Int 2016:1879837

23. Jiang S, Tian G, Li X, Yang Z, Wang F, Tia Z, Huang B, Wei F, Zha K, Sun Z, Sui X, Liu S, Guo W, Guo Q (2021) Research Progress on Stem Cell Therapies for Articular Cartilage Regeneration. Stem Cells Int 2021:882505

24. Filardo G, Perssida F, Roff F, Manreddi M, Kon E (2016) Stem cells in articular cartilage regeneration. J Orthop Surg Res 11:42

25. Fuentes-Boquete IM, de Toro-Santos FJ, Blanco-Garcia FJ, Diaz-Prado SM (2018) Induced pluripotent stem cells for cartilage repair: current status and future perspectives. Eur Cells Mater 36:96–109

26. Stenert AF, Noth U, Tuan RS (2008) Concepts in gene therapy for cartilage repair. Injury 39(1):113–119

27. Dominici M, Pritchard C, Garlits JE, Hofmann TJ, Persons DA, Horwitz EM (2004) Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation. Proc Natl Acad Sci U S A 101:11761–11766

28. Kacena MA, Gundberg CM, Horwitz MC (2006) A reciprocal regulatory interaction between megacaryocytes, bone cells and hematopoietic stem cells. Bone 39:978–984

29. Olmsted-Davis EA, Gugala Z, Camargo F, Gannon FH, Jackson K, Kienstra M, Faccini R, Facchini A (2003) Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proc Natl Acad Sci U S A 100:15877–15882

30. Cavallo C, Desando G, Cumborino M, Ferrari A, Zini N, Facchini A, Grigolo B (2013) Chondrogenic differentiation of bone marrow concentrate grown onto a hyaluronan scaffold: rationale for its use in the treatment of cartilage lesions. J Biomed Mater Res A 101(6):1559–1570

31. Cavallo C, Desando G, Cattini L, Cavallo M, Buda R, Giannini S, Facchini A, Grigolo B (2013) Bone marrow concentrated cell transplantation: rationale for its use in the treatment of human osteochondral lesions. J Biol Regul Homeost Agents 27(1):165–175

32. Grigolo B, Cavallo C, Desando G, Manfredini C, Lisiognoli G, Ferrari A, Zini N, Facchini A (2015) Novel nano-composite biomimetic biomaterial allows chondrogenic and osteogenic differentiation of bone marrow concentrate derived cells. J Mater Sci Mater Med 26(4):173

33. Pak J, Lee JH, Pak N, Pak Y, Park KS, Jeon JH, Jeong BC, Lee SH (2018) Cartilage Regeneration in Humans with Adipose Tissue-Derived Stem Cells and Adipose Stromal Vascular Fraction Cells: Updated Status. Int J Mol Sci 19(7):2146

34. Murphy MB, Moncivais K, Caplan AI (2013) Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 45(11):e54

35. Veronesi F, Borsari V, Sartori M, Orciani M, Mattiodi-Belmonte M, Fini M (2016) The use of cell conditioned medium for musculoskeletal tissue regeneration. J Cell Physiol 231(6):4423–4442

36. D’Arrigo D, Roffi A, Cucchiari M, Moretti M, Candrian C, Filardo G (2019) Secretome and extracellular vesicles as new biological therapies for knee osteoarthritis: a systematic review. J Clin Med 8(1):1867

37. Rani S, Ryan AE, Griffin MD, Ritter T (2015) Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. Mol Ther 23(5):812–823

38. Fortier LA, Barker U, Strauss EJ, McCarrel TM, Cole B (2011) The role of growth factors in cartilage repair. Clin Orthop Relat Res 469(10):2706–2715

39. Subbiah R, Goldberg RE (2019) Materials science and design principles of growth factor delivery systems in tissue engineering and regenerative medicine. Adv Health Mater 8(1):e801000

40. Anitua E, Sánchez M, Nurden AT et al (2006) New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 24:227–234

41. Mlynarek RA, Kuhn AW, Bedi A (2016) Platelet-Rich Plasma (PRP) in Orthopedic Sports Medicine. Am J Orthod Dentofacial Orthop 45(5):290–326

42. Abrams GD, Frank RM, Fortier LA, Cole BJ (2013) Platelet-rich plasma for articular cartilage repair. Sports Med Arthrosc Rev 21(4):213–219

43. Wasyleczko M, Sikorska W, Chwojnowski A (2020) Review of Synthetic and Hybrid Scaffolds in Cartilage Tissue Engineering. Membranes 10(11):348

44. Theodoridis K, Manthou ME, Argiladou E, Kritis A (2022) In vivo cartilage regeneration with cell-seeded natural biomaterial scaffold implants: 15-year study. Tissue Eng Part B Rev 28:206–245

45. De Franceschi L, Grigolo B, Roseti L, Facchini A, Fini M, Gaivaresi G, Tschon M, Giardino R (2005) Transplantation of chondrocytes seeded on collagen-based scaffold in cartilage defects in rabbits. J Biomed Mater Res 75A:612–622

46. Facchini A, Lisiognoli G, Cristosi S, Roseti L, De Franceschi L, Marconi EG, B (2006) Human chondrocytes and mesenchymal stem cells grown onto engineered scaffold. Biomech 43(34):471–480

47. Grigolo B, De Franceschi L, Roseti L, Cattini L, Facchini A (2005) Down regulation of degenerative cartilage molecules in chondrocytes grown on a hyaluronan-based scaffold. Biomaterials 26(28):5668–5676

48. Grigolo B, Desando G, Cavallo C, Zini N, Ghisu S, Facchini A (2011) Evaluation of chondrocyte behavior in a new equine collagen scaffold useful for cartilage repair. J Biol Regul Homeost Agents 25(2):553–562

49. Grigolo B, Lisiognoli G, Piaicentini A, Fiorini M, Gobbi P, Mazzotti D, Mavesio A, Facchini A (2002) Evidence for redifferentiation of human chondrocytes grown on a hyaluronan-based biomaterial (Hyaff 11): molecular immunohistochemical and ultrastructural analysis. Biomaterials 23(4):1187–1195

50. Grigolo B, Roseti L, Fiorini M, Fini M, Gaivares iG, cdini NN, Giardino R, Facchini A (2001) Transplantation of chondrocytes seeded on a hyaluronan derivative (hyaff-11) into cartilage defects in rabbits. Biomaterials 22(17):2417–2424

51. Fu L, Li P, Li H, Gao C, Yang Z, Zhao T, Chen W, Liao Z, Peng Y, Cao F, Sun X, Liu S, Guo Q (2021) The application of bioelectrodes for cartilage tissue engineering: advances limitations and future perspectives. Stem Cells Int 6621806:13

52. Chia HN, Wu BM (2015) Recent advances in 3D printing of biomaterials. J Biol Eng 9:44

53. Javad M, Haleem A (2019) Current status and challenges of additive manufacturing in orthopaedics: an overview. J Clin Orthopa Trauma 10(2):380–386

54. Xu J, Ji J, Jiao J, Zheng L, Hong Q, Tang H, Zhang S, Qu X, Yue B (2022) 3D printing for bone-cartilage interface regeneration. Front Bioeng Biotechnol 10828921

55. Jeong CG, Atala A (2015) 3D printing and biofabrication for load bearing tissue engineering. Adv Exp Med Biol 881:3–14

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.